Search
Displaying 631–640 of 929 results for “vision connection”
-
Foundation Fighting Blindness Hosts Chicago Night for Sight Event
Foundation NewsThe October 5th event will raise awareness and fund research driving treatments and cures for blinding diseases and macular degeneration.
-
Foundation News
The four-year study will inform clinical trial design for emerging USH3 therapies.
-
AREDS Formula Reduces Risk of Visual Acuity Loss for People with Geographic Atrophy
Research NewsPreviously, the formula was thought to only reduce risk of early age-related macular degeneration advancing to late-stage disease
-
Eye on the Cure Podcast | Episode 70: Karen Petrou
Eye on the CureKaren Petrou, the new board chair at the Foundation, talks to host Ben Shaberman about her vision for the Foundation moving forward. Karen has been an active director on the Foundation’s board for nearly two decades. She is co-founder and managing partner of Federal Financial Analytics, a firm providing analytical and advisory services on legislative, regulatory, and public-policy issues affecting financial services companies. Karen has RP and lives in Washington, DC, with her guide dog, Ike.
-
Eye on the Cure Podcast | Episode 68: Dr. Michael Telias
Eye on the CureFor this episode of Eye on the Cure, Michael Telias, PhD, an assistant professor at the University of Rochester in New York, talks with host Ben Shaberman about forthcoming clinical trials to evaluate the FDA-approved drug disulfiram (aka, Antabuse) for improving vision in people with retinitis pigmentosa and other retinal diseases. Disulfiram was originally developed to deter people from abusing alcohol.
-
Research News
No serious adverse events were reported. One patient had encouraging improvement in retinal sensitivity.
-
Beacon Stories
We’re honoring National DNA Day with the Danny family! When Sarah and A. J. found out their oldest daughter Lucia had Stargardt disease, it was a challenge to process her diagnosis. And then they realized their other five children could also be affected. Through genetic testing, they learned their five-year-old daughter Sarafina also has Stargardt disease. Now, Lucia and Sarafina have a bond like no other, and call each other the “Stargardt Sisters.”
-
Phase 3 Clinical Trial of NAC Launched for RP Patients
Research NewsThe drug is thought to work independent of the mutated gene causing RP.
-
Ocugen to Launch Phase 3 Clinical Trial of Modifier Gene Therapy for RP
Research NewsThe emerging treatment is designed to work independent of the patient’s mutated gene.
-
Eye on the Cure Podcast | Episode 61: Dr. Jose Sahel
Eye on the CureDr. Jose Sahel, one of the most honored and accomplished leaders in the retinal disease research space, talks with host Ben Shaberman about his establishment and leadership of renowned ophthalmology clinical research centers at the University of Pittsburgh Medical Center and Institut de la Vision in Paris. They also discuss emerging inherited retinal disease therapies from SparingVision, a biotech co-founded by Dr. Sahel.
.png)
